Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
October 31, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
October 19, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global...
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
October 10, 2023 07:30 ET
|
Zevra Therapeutics
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
October 05, 2023 07:30 ET
|
Zevra Therapeutics
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra...
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
October 02, 2023 07:30 ET
|
Zevra Therapeutics
Data generated to date indicate SDX is well-tolerated across all doses and both dosing regimens studied, laying the groundwork for future Phase 3 trial Topline data from completed trial expected in...
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
September 20, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive...
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023
September 09, 2023 20:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation...
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive...
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
August 31, 2023 07:30 ET
|
Zevra Therapeutics; Acer Therapeutics Inc.
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization...
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
August 14, 2023 07:30 ET
|
Zevra Therapeutics
Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million...